- en
This keynote delves into the translation of innovations from the human health (HH) sector into the animal health (AH) domain—whether through the adaptation of mature technologies or through concurrent development strategies. It will explore the opportunities, complexities, and critical success factors that influence this journey.
The session begins with presentations illustrating the pathway of specific technologies—such as antibody-based therapeutics—from human to animal application. These talks will highlight the scientific, regulatory, and market considerations that must be addressed when transitioning technologies across sectors, especially when targeting different species such as companion animals or livestock.
A panel discussion will follow, tackling the broader context and challenges of this translation. Topics will include the structural differences between HH and AH industries, such as funding models, disease models, and risk tolerance. Panelists will explore key drivers of successful translation—like technology scalability, regulatory alignment, intellectual property strategy, and market readiness.
The discussion will also reflect on emerging trends, including personalized medicine, digital health, and advanced biologics, and assess their relevance, feasibility, and value within AH. The session aims to offer a realistic view of what it takes to bring innovation from bench to barn or home.
